Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:

NCT ID: NCT05638802 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Start date: June 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.

NCT ID: NCT05637112 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

ASTER
Start date: February 27, 2023
Phase:
Study type: Observational

Anifrolumab Study of Treatment Effectiveness in the Real World (ASTER) study will collect real world data to obtain a good understanding of the (sustained) clinical effect and patient quality of life outcomes among diagnosed SLE patients who initiate anifrolumab treatment. ASTER will generate critical real-world evidence on the benefits of adding anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients.

NCT ID: NCT05636670 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease

Start date: October 1, 2022
Phase:
Study type: Observational

Based on clinical manifestations, laboratory data and intestinal microflora detection, the cognitive function characteristics of patients with systemic lupus erythematosus and cerebrovascular disease and its relationship with intestinal microflora were analyzed to explore the possible pathogenesis of lupus cerebrovascular disease.

NCT ID: NCT05632029 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Laser Acupuncture in Egyptian Systemic Lupus Females With Insulin Resistance

Start date: October 20, 2022
Phase: N/A
Study type: Interventional

glucose hemosatasis, oxidative stress, abnormalities of blood pressures, and high inflammatory status is high presented in lupus patients.

NCT ID: NCT05631717 Recruiting - Clinical trials for Systemic Lupus Erythematosus

The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN

Start date: October 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of human umbilical cord mesenchymal stem cells and low-dose IL-2 in the treatment of LN

NCT ID: NCT05629208 Recruiting - Clinical trials for Cutaneous Lupus Erythematosus (CLE)

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Start date: April 17, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.

NCT ID: NCT05624749 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

SIRIUS-SLE 2
Start date: April 21, 2023
Phase: Phase 3
Study type: Interventional

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

NCT ID: NCT05620407 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

POETYK SLE-2
Start date: January 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

NCT ID: NCT05617677 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

POETYK SLE-1
Start date: January 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

NCT ID: NCT05607368 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

Mast Cells Are Involved in the Mechanism of NPSLE Epilepsy

Start date: January 1, 2022
Phase:
Study type: Observational

Tryptase, TLR4, and anti-NR2A antibodies were measured in serum, cerebrospinal fluid, and subjects and other markers to assess their relevance to disease activity, aiming to find new therapeutic targets,Timely intervention to improve the prognosis of SLE and improve the quality of life of patients with SLE.